STOCK TITAN
  1. Home
  2. Sec-filings
  3. AVIR
  4. [Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity

Atea Pharmaceuticals (AVIR) director receives new options and RSU awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Atea Pharmaceuticals director Bruce Polsky reported routine equity compensation changes. On June 18, 2026, he exercised 29,600 restricted stock units into Common Stock at no cost, bringing his direct Common Stock holdings to 124,806 shares.

He also received new awards: a stock option for 37,700 shares of Common Stock at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, in each case subject to continued service. The filing shows no share sales, only grants and exercises related to compensation.

Positive

  • None.

Negative

  • None.
Insider Polsky Bruce
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 29,600 $0.00 --
Grant/Award Restricted Stock Units 26,700 $0.00 --
Grant/Award Stock Option (Right to Buy) 37,700 $0.00 --
Exercise Common Stock 29,600 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Stock Option (Right to Buy) — 37,700 shares (Direct, null); Common Stock — 124,806 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested in full on June 18, 2026. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
RSUs exercised into Common Stock 29,600 shares Exercised on June 18, 2026
Common Stock held after transactions 124,806 shares Post-transaction direct ownership
New stock option grant 37,700 options Grant on June 18, 2026
Stock option exercise price $4.36 per share Conversion/exercise price of new option grant
New RSU grant 26,700 RSUs Grant on June 18, 2026
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 4.3600 per share."
Exercise or conversion of derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security."
Grant, award, or other acquisition financial
"Transaction code A is described as Grant, award, or other acquisition."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Polsky Bruce
(Last)(First)(Middle)
225 FRANKLIN STREET
SUITE 2100
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026M29,600A$0(1)124,806D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/18/2026M29,600 (2) (2)Common Stock29,600$00D
Restricted Stock Units(1)06/18/2026A26,700 (3) (3)Common Stock26,700$026,700D
Stock Option (Right to Buy)$4.3606/18/2026A37,700 (4)06/17/2036Common Stock37,700$037,700D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. The RSUs vested in full on June 18, 2026.
3. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
4. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
/s/ Andrea Corcoran, as Attorney-in-Fact for Bruce Polsky06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Atea Pharmaceuticals (AVIR) director Bruce Polsky report?

Bruce Polsky reported exercising 29,600 restricted stock units into Common Stock and receiving new awards of 37,700 stock options and 26,700 restricted stock units, all dated June 18, 2026, as part of his equity compensation.

Did Bruce Polsky buy or sell Atea Pharmaceuticals (AVIR) shares in the open market?

The Form 4 shows no open-market buys or sells. It reports only equity compensation activity: exercises of restricted stock units into Common Stock and grants of new stock options and restricted stock units on June 18, 2026.

How many Atea Pharmaceuticals (AVIR) shares does Bruce Polsky hold after these transactions?

After exercising 29,600 restricted stock units, Bruce Polsky directly holds 124,806 shares of Atea Pharmaceuticals Common Stock, according to the Form 4’s post-transaction ownership figure for his non-derivative holdings.

What are the terms of Bruce Polsky’s new Atea Pharmaceuticals (AVIR) stock options?

Bruce Polsky received stock options covering 37,700 shares of Common Stock at an exercise price of $4.36 per share, vesting in twelve substantially equal monthly installments after June 18, 2026 and becoming fully vested by June 18, 2027, subject to continued service.

When do Bruce Polsky’s new Atea Pharmaceuticals (AVIR) restricted stock units vest?

The new grant of 26,700 restricted stock units vests in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, provided Bruce Polsky continues serving through the applicable vesting date.